These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 'Faith Healing' and 'Subtraction Anxiety' in Unblinded Trials of Procedures: Lessons from DEFER and FAME-2 for End Points in the ISCHEMIA Trial. Rajkumar CA; Nijjer SS; Cole GD; Al-Lamee R; Francis DP Circ Cardiovasc Qual Outcomes; 2018 Mar; 11(3):e004665. PubMed ID: 29530888 [No Abstract] [Full Text] [Related]
5. BARI 2D: headlines are not enough. King SB JACC Cardiovasc Interv; 2009 Aug; 2(8):809-10. PubMed ID: 19695556 [No Abstract] [Full Text] [Related]
6. Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial? Cheng-Torres KA; Desai KP; Sidhu MS; Maron DJ; Boden WE Future Cardiol; 2016 Jan; 12(1):35-44. PubMed ID: 26696561 [TBL] [Abstract][Full Text] [Related]
14. An orwellian discourse on the meaning and measurement of noninferiority. Diamond GA; Kaul S Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435 [TBL] [Abstract][Full Text] [Related]
15. [Practice guidelines for therapy of patients with ischemic heart disease]. Yokoyama M Nihon Naika Gakkai Zasshi; 2002 Mar; 91(3):991-1005. PubMed ID: 11985112 [No Abstract] [Full Text] [Related]
16. [Introduction to randomized trials: the choice of endpoint]. Simon EG; Fouché CJ; Perrotin F Gynecol Obstet Fertil; 2011 Oct; 39(10):595-6. PubMed ID: 21924939 [No Abstract] [Full Text] [Related]
17. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise? Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470 [No Abstract] [Full Text] [Related]
18. Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. Ennezat PV; Le Jemtel T; Cosgrove S; Hallas J; Hansen MR Acta Cardiol; 2020 Feb; 75(1):10-19. PubMed ID: 30513258 [No Abstract] [Full Text] [Related]